Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

iate the TIME-1 trial at the end of 2007 or early 2008.

"Kosan's successful completion of both the Special Protocol Assessment process with the FDA and Scientific Advice from the EMEA for our TIME-1 trial provides us with a clear roadmap to registration in major countries around the world for this potentially important new treatment for patients with multiple myeloma," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that Kosan's TIME program is the most advanced Hsp90 inhibitor clinical program in the industry, underscoring Kosan's leadership in this promising new class of anticancer therapies. We appreciate the widespread support we have received from the US and international myeloma clinician and patient communities."

About TIME

The TIME clinical program utilizes Kosan's improved, proprietary injectable suspension formulation of tanespimycin. The injectable suspension formulation is designed to provide important benefits, including improved patient safety, due to the elimination of Cremophor(R) and the associated need for steroid premedication to prevent hypersensitivity reactions. Tanespimycin injectable suspension also has a potentially enhanced intellectual property position and permits easier drug preparation and administration compared to the prior formulation.

The TIME-1 trial will be an open-label, randomized, multi-center trial conducted in the US and in Europe that is designed to enroll over 450 patients with relapse of multiple myeloma following a single prior course of treatment (first-relapse). The trial is designed to compare two groups: patients treated with bortezomib plus tanespimycin and patients treated with bortezomib alone. Tanespimycin will be administered at a dose of 340 mg/m2 and all patients will receive standard doses of bortezomib (1.3 mg/m2). TIME-1 is designed with a primary endpoint of progression-free survival. TIME-1 is designed to include an interim analys
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... 2014 Breckenridge Pharmaceutical, Inc. announced today that ... Laboratories Pvt. Ltd. ( Hyderabad, India ) ... new ANDAs.  Under the terms of the agreement, MSN ... Breckenridge for the U.S. market, and Breckenridge will market ... MSN have agreed to develop an oral antibiotic with ...
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... SKILLMAN, N.J., Feb. 7, 2011 ConvaTec, a world-leading ... and hospital care, today announced the appointment of several ... Nino Pionati has been appointed President, Intercontinental in ... Latin America and Canada. These markets continue to be ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... first in class collagenase-based products, today announced that its ... "Rights Agreement"), adopted May 14, 2002 and previously amended ... increases the ownership threshold for determining "Acquiring Person" status ...
Cached Medicine Technology:ConvaTec Announces New Appointments to Leadership Team 2
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
(Date:12/19/2014)... Florida (PRWEB) December 19, 2014 Sub Zero ... to sponsor a blood drive Sunday the 28th from 2pm-6pm ... Road & Sawyer Road in Sarasota, FL. , Inquiries regarding ... thank you for participating in the donating process, Sub Zero ... free flash frozen, custom ice cream. , About Sub Zero ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... dedicated to developing educational events, tools and resources ... Rouxbe Cooking School , the world’s leading online ... prescription every human being needs: Culinary Rx. As ... cooking course, Culinary Rx, scheduled for debut spring ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... Massachusetts General Hospital (MGH), together with a coalition of ... world,s largest registry of patients who have had optical ... an intravascular imaging technology that researchers hope will give ... plaques that cause heart attacks and sudden cardiac death. ...
... finds , THURSDAY, March 25 (HealthDay News) -- More than ... said that they drank alcohol in the past month, according ... The analysis of 2006-2008 data from the National Survey on ... rates were as high as 40 percent in some states, ...
... The effectiveness of ordinary surgical masks as opposed to ... H1N1 influenza virus has been the subject of debate. ... issue of Clinical Infectious Diseases, available online ... as effective as respirators in this regard. ...
... ... strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s disease. ... San Francisco, CA (Vocus) ... symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ,The ...
... This press release is available in French . ... a previously hidden channel to attack leukemia and other cancer ... Journal of Biological Chemistry . The findings from the Universit ... way doctors treat cancer patients. "We found a gateway, ...
... survey finds , THURSDAY, March 25 (HealthDay News) ... likely to be chronically offline: they use the Internet ... , The survey, conducted by the Pew Internet & ... published online March 24, found that just 62 percent ...
Cached Medicine News:Health News:Mass. General Hospital to create registry for coronary optical coherence tomography 2Health News:Underage Drinking Soars in U.S. 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:New gateway to treat leukemia and other cancers 2Health News:Chronic Disease Linked to Less Internet Usage 2
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... quality control material used for monitoring the ... on CO-Oximeter instrumentation. It provides an alternative ... the human physiologic range for tHb, O2Hb, ... three (3) levels for monitoring analyzer performance ...
... 233 is an assayed quality ... the measurements of total hemoglobin ... instrumentation. It is available in ... analyzer performance at varying points ...
... QC 623 is an assayed quality control material ... available in four (4) levels for monitoring analyzer ... It may be used on multiple test analyzers ... the Radiometer 600). QC623 is also for use ...
Medicine Products: